Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Open accessThe DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Abstract
This Position Paper aims to review and discuss the available data on therapeutic drug monitoring (TDM) of antibacterials, antifungals and antivirals in critically ill adult patients in the intensive care unit (ICU). This Position Paper also provides a practical guide on how TDM can be applied in routine clinical practice to improve therapeutic outcomes in critically ill adult patients. Literature review and analysis were performed by Panel Members nominated by the endorsing organisations, European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/Pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and International Society of Antimicrobial Chemotherapy (ISAC). Panel members made recommendations for whether TDM should be applied clinically for different antimicrobials/classes. TDM-guided dosing has been shown to be clinically beneficial for aminoglycosides, voriconazole and ribavirin. For most common antibiotics and antifungals in the ICU, a clear therapeutic range has been established, and for these agents, routine TDM in critically ill patients appears meritorious. For the antivirals, research is needed to identify therapeutic targets and determine whether antiviral TDM is indeed meritorious in this patient population. The Panel Members recommend routine TDM to be performed for aminoglycosides, beta-lactam antibiotics, linezolid, teicoplanin, vancomycin and voriconazole in critically ill patients. Although TDM should be the standard of care for most antimicrobials in every ICU, important barriers need to be addressed before routine TDM can be widely employed worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
J Antimicrob Chemother 1994; 33: 350–351
O'SHAUGHNESSY, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,746
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B., Fridkin, S., & National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities (2013) · Infection Control & Hospital Epidemiology · doi:10.1086/668770 · Cited by 1,582
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
Self-citationRoberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Self-citationPascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Bennett, J. E., Dismukes, W. E., Duma, R. J., Medoff, G., Sande, M. A., Gallis, H., Leonard, J., Fields, B. T., Bradshaw, M., Haywood, H., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907193010303 · Cited by 863
Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki079 · Cited by 549
Blaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464
Sandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit334 · Cited by 430
Drusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426
A suggested approach to once‐daily aminoglycoside dosing.
Begg, E., Barclay, M., & Duffull, S. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05719.x · Cited by 420
Subtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414
Self-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 1×
“acyclovir, aminoglycosides, beta-lactams, daptomycin, fluconazole and glycopeptides), this can result in a significantly expanded Vd [7].”
BackgroundPark, W. B., Kim, N.-H., Kim, K.-H., Lee, S. H., Nam, W.-S., Yoon, S. H., Song, K.-H., Choe, P. G., Kim, N. J., Jang, I.-J., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis599 · Cited by 399
Voriconazole therapeutic drug monitoring
Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1570-1572.2006 · Cited by 399
Weller, S., Blum, M. R., Doucette, M., Burnette, T., Cederberg, D. M., de Miranda, P., & Smiley, M. L. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.196 · Cited by 395
Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?
Neely, M. N., Youn, G., Jones, B., Jelliffe, R. W., Drusano, G. L., Rodvold, K. A., & Lodise, T. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-13 · Cited by 392
Self-citationTreatment of invasive aspergillosis with itraconazole
Denning, D. W., Tucker, R. M., Hansen, L. H., & Stevens, D. A. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90475-0 · Cited by 364
Neely, M. N., Kato, L., Youn, G., Kraler, L., Bayard, D., van Guilder, M., Schumitzky, A., Yamada, W., Jones, B., & Minejima, E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02042-17 · Cited by 359
Self-citationPrinciples of antibacterial dosing in continuous renal replacement therapy
Choi, G., Gomersall, C. D., Tian, Q., Joynt, G. M., Freebairn, R., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181aab3d0 · Cited by 334
The Clinical Relevance of Plasma Protein Binding Changes
Roberts, J. A., Pea, F., & Lipman, J. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0018-5 · Cited by 329
Self-citationMIC-based dose adjustment: facts and fables
Mouton, J. W., Muller, A. E., Canton, R., Giske, C. G., Kahlmeter, G., & Turnidge, J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx427 · Cited by 328
Vardakas, K. Z., Voulgaris, G. L., Maliaros, A., Samonis, G., & Falagas, M. E. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30615-1 · Cited by 327
Pogue, J. M., Lee, J., Marchaim, D., Yee, V., Zhao, J. J., Chopra, T., Lephart, P., & Kaye, K. S. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir611 · Cited by 327
Rayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C., & Schentag, J. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00007 · Cited by 306
Pharmacokinetics of itraconazole following oral administration to normal volunteers
Hardin, T. C., Graybill, J. R., Fetchick, R., Woestenborghs, R., Rinaldi, M. G., & Kuhn, J. G. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.9.1310 · Cited by 299
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Dolton, M. J., Ray, J. E., Chen, S. C.-A., Ng, K., Pont, L. G., & McLachlan, A. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00626-12 · Cited by 290
Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections
Li, C., Du, X., Kuti, J. L., & Nicolau, D. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00294-06 · Cited by 289
Udy, A. A., Baptista, J. P., Lim, N. L., Joynt, G. M., Jarrett, P., Wockner, L., Boots, R. J., & Lipman, J. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000029 · Cited by 280
Self-citationBhavnani, S. M., Rubino, C. M., Ambrose, P. G., & Drusano, G. L. (2010) · Clinical Infectious Diseases · doi:10.1086/652767 · Cited by 280
Dosing guidance for intravenous colistin in critically-ill patients.
Nation, R. L., Garonzik, S. M., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Forrest, A., Paterson, D. L., Li, J., & Silveira, F. P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw839 · Cited by 262
Pharmacodynamics of cefepime in patients with Gram-negative infections
Tam, V. H. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf130 · Cited by 262
Mendel, D. B., Tai, C. Y., Escarpe, P. A., Li, W., Sidwell, R. W., Huffman, J. H., Sweet, C., Jakeman, K. J., Merson, J., Lacy, S. A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.640 · Cited by 255
Wheat, J., Hafner, R., Korzun, A. H., Limj, M. T., Spencer, P., Larsen, R. A., Hecht, F. M., & Powderly, W. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80311-8 · Cited by 245
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
Stamm, A. M., Diasio, R. B., Dismukes, W. E., Shadomy, S., Cloud, G. A., Bowles, C. A., Karam, G. H., & Espinel-Ingroff, A. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90691-7 · Cited by 244
van Lent-Evers, N. A. E. M., Mathôt, R. A. A., Geus, W. P., van Hout, B. A., & Vinks, A. A. T. M. M. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199902000-00010 · Cited by 244
Finch, N. A., Zasowski, E. J., Murray, K. P., Mynatt, R. P., Zhao, J. J., Yost, R., Pogue, J. M., & Rybak, M. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01293-17 · Cited by 241
Jang, S. H., Colangelo, P. M., & Gobburu, J. V. S. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.64 · Cited by 239
Mohamed, A. F., Karaiskos, I., Plachouras, D., Karvanen, M., Pontikis, K., Jansson, B., Papadomichelakis, E., Antoniadou, A., Giamarellou, H., Armaganidis, A., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06426-11 · Cited by 234
Trifilio, S., Singhal, S., Williams, S., Frankfurt, O., Gordon, L., Evens, A., Winter, J., Tallman, M., Pi, J., & Mehta, J. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705754 · Cited by 229
Sorlí, L., Luque, S., Grau, S., Berenguer, N., Segura, C., Montero, M. M., Álvarez-Lerma, F., Knobel, H., Benito, N., & Horcajada, J. P. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-380 · Cited by 225
Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Warren, S. J. C., Gao, W., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01485-12 · Cited by 224
Posaconazole: A Broad-Spectrum Triazole Antifungal Agent
Nagappan, V., & Deresinski, S. (2007) · Clinical Infectious Diseases · doi:10.1086/523576 · Cited by 223
Troke, P. F., Hockey, H. P., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-10 · Cited by 218
Itraconazole Therapy for Cryptococcal Meningitis and Cryptococcosis
Denning, D. W. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.10.2301 · Cited by 215
Wong, G., Brinkman, A., Benefield, R. J., Carlier, M., De Waele, J. J., El Helali, N., Frey, O., Harbarth, S., Huttner, A., McWhinney, B., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt523 · Cited by 215
Self-citationBaptista, J. P., Udy, A. A., Sousa, E., Pimentel, J., Wang, L., Roberts, J. A., & Lipman, J. (2011) · Critical Care · doi:10.1186/cc10262 · Cited by 211
Self-citationReitano, M., Tyring, S., Lang, W., Thoming, C., Worm, A. ‐., Borelli, S., Chambers, L. O., Robinson, J. M., Corey, L., & the International Valaciclovir HSV Study Group (1998) · The Journal of Infectious Diseases · doi:10.1086/515385 · Cited by 209
Roberts, D. M., Roberts, J. A., Roberts, M. S., Liu, X., Nair, P., Cole, L., Lipman, J., & Bellomo, R. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e318241e553 · Cited by 207
Self-citationPascual, A., Csajka, C., Buclin, T., Bolay, S., Bille, J., Calandra, T., & Marchetti, O. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis437 · Cited by 207
Cheah, S.-E., Wang, J., Nguyen, V. T. T., Turnidge, J. D., Li, J., & Nation, R. L. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv267 · Cited by 206
Cataldo, M. A., Tacconelli, E., Grilli, E., Pea, F., & Petrosillo, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr442 · Cited by 204
Self-citationTherapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis
Pea, F., Furlanut, M., Cojutti, P., Cristini, F., Zamparini, E., Franceschi, L., & Viale, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00177-10 · Cited by 198
Self-citationAntifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels
Boogaerts, M. A., Verhoef, G. E., Zachee, P., Demuynck, H., Verbist, L., & De Beule, K. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02299.x · Cited by 189
Sumi, C. D., Heffernan, A. J., Lipman, J., Roberts, J. A., & Sime, F. B. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00791-z · Cited by 181
Self-citationOptimising drug dosing in patients receiving extracorporeal membrane oxygenation
Cheng, V., Abdul-Aziz, M.-H., Roberts, J. A., & Shekar, K. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.09.154 · Cited by 177
Self-citationClancy, C. J., Yu, V. L., Morris, A. J., Snydman, D. R., & Nguyen, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3171-3177.2005 · Cited by 176
Cornely, O. A., Duarte, R. F., Haider, S., Chandrasekar, P., Helfgott, D., Jiménez, J. L., Candoni, A., Raad, I., Laverdiere, M., Langston, A., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv380 · Cited by 171
Wong, G., Briscoe, S., McWhinney, B., Ally, M., Ungerer, J., Lipman, J., & Roberts, J. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky314 · Cited by 169
Self-citationUpdated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
Nation, R. L., Garonzik, S. M., Li, J., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Paterson, D. L., Turnidge, J. D., Forrest, A., & Silveira, F. P. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ964 · Cited by 168
Thicot, G., Joosten, E., Boogaerts, M. A., Vande Pitte, J., & Cauwenbergh, G. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.supplement_1.s94 · Cited by 162
Voriconazole metabolism is influenced by severe inflammation: a prospective study
Veringa, A., ter Avest, M., Span, L. F. R., van den Heuvel, E. R., Touw, D. J., Zijlstra, J. G., Kosterink, J. G. W., van der Werf, T. S., & Alffenaar, J.-W. C. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw349 · Cited by 161
Self-citationVoriconazole concentrations and outcome of invasive fungal infections
Miyakis, S., van Hal, S. J., Ray, J., & Marriott, D. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02990.x · Cited by 159
Self-citationPai, M. P., Turpin, R. S., & Garey, K. W. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-06 · Cited by 159
Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing
Mahmoud, S. H., & Shen, C. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9030036 · Cited by 158
High-dose itraconazole in the treatment of severe mycoses
Sharkey, P. K., Rinaldi, M. G., Dunn, J. F., Hardin, T. C., Fetchick, R. J., & Graybill, J. R. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.707 · Cited by 154
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis
Louie, A., Drusano, G. L., Banerjee, P., Liu, Q.-F., Liu, W., Kaw, P., Shayegani, M., Taber, H., & Miller, M. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1105 · Cited by 154
Spruance, S. L. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.15.1729 · Cited by 153
Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring
Imhof, A., J. Schaer, D., Schwarz, U., & Schanz, U. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11547 · Cited by 151
Roberts, J. A., Joynt, G. M., Lee, A., Choi, G., Bellomo, R., Kanji, S., Mudaliar, M. Y., Peake, S. L., Stephens, D., Taccone, F. S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa224 · Cited by 151
Self-citationBone Marrow Toxicity Associated with 5-Fluorocytosine Therapy
Kauffman, C. A., & Frame, P. T. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.2.244 · Cited by 150
Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
Glasmacher, A., Hahn, C., Leutner, C., Molitor, E., Wardelmann, E., Losem, C., Sauerbruch, T., Marklein, G., & Schmidt‐Wolf, I. G. H. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00505.x · Cited by 147
Safety, Plasma Concentrations, and Efficacy of High-Dose Fluconazole in Invasive Mold Infections
Anaissie, E. J., Kontoyiannis, D. P., Huls, C., Vartivarian, S. E., Karl, C., Prince, R. A., Bosso, J., & Bodey, G. P. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/172.2.599 · Cited by 147
Broeker, A., Nardecchia, M., Klinker, K. P., Derendorf, H., Day, R. O., Marriott, D. J. E., Carland, J. E., STOCKER, S. L., & Wicha, S. G. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.02.029 · Cited by 144
Self-citationDesai, A., Kovanda, L., Kowalski, D., Lu, Q., Townsend, R., & Bonate, P. L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02819-15 · Cited by 143
Landersdorfer, C. B., Wang, J., Wirth, V., Chen, K., Kaye, K. S., Tsuji, B. T., Li, J., & Nation, R. L. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx409 · Cited by 143
Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials
Andes, D. R., Kovanda, L. L., Desai, A. V., Kitt, T. M., Zhao, M., & Walsh, T. J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00585-18 · Cited by 143
Walravens, J., Brouwers, J., Spriet, I., Tack, J. F., Annaert, P., & Augustijns, P. (2011) · Clinical Pharmacokinetics · doi:10.2165/11592630-000000000-00000 · Cited by 140
Rodríguez-Tudela, J. L., Almirante, B., Rodríguez-Pardo, D., Laguna, F., Donnelly, J. P., Mouton, J. W., Pahissa, A., & Cuenca-Estrella, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-07 · Cited by 137
Matsumoto, K., Ikawa, K., Abematsu, K., Fukunaga, N., Nishida, K., Fukamizu, T., Shimodozono, Y., Morikawa, N., Takeda, Y., & Yamada, K. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.01.008 · Cited by 136
Ueda, K., Nannya, Y., Kumano, K., Hangaishi, A., Takahashi, T., Imai, Y., & Kurokawa, M. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0296-3 · Cited by 135
The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs
Tabah, A., De Waele, J., Lipman, J., Zahar, J. R., Cotta, M. O., Barton, G., Timsit, J.-F., & Roberts, J. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv165 · Cited by 134
Self-citationMitsani, D., Nguyen, M. H., Shields, R. K., Toyoda, Y., Kwak, E. J., Silveira, F. P., Pilewski, J. M., Crespo, M. M., Bermudez, C. A., Bhama, J. K., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05219-11 · Cited by 133
Alobaid, A. S., Hites, M., Lipman, J., Taccone, F. S., & Roberts, J. A. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.01.009 · Cited by 131
Self-citationToxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring
Lestner, J. M., Roberts, S. A., Moore, C. B., Howard, S. J., Denning, D. W., & Hope, W. W. (2009) · Clinical Infectious Diseases · doi:10.1086/605499 · Cited by 129
Cartledge, J. D., Midgely, J., & Gazzard, B. G. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.6.477 · Cited by 126
Udy, A. A., Dulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A. R., Bellomo, R., Gomersall, C. D., Shirwadkar, C., Eastwood, G. M., Myburgh, J., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.022 · Cited by 123
Self-citationAndes, D., Ambrose, P. G., Hammel, J. P., Van Wart, S. A., Iyer, V., Reynolds, D. K., Buell, D. N., Kovanda, L. L., & Bhavnani, S. M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01430-10 · Cited by 119
Adverse Effects of High-Dose Intravenous Acyclovir in Ambulatory Patients with Acute Herpes Zoster
Bean, B., & Aeppli, D. M. (1985) · The Journal of Infectious Diseases · doi:10.1093/infdis/151.2.362 · Cited by 118
de Montmollin, É., Bouadma, L., Gault, N., Mourvillier, B., Mariotte, É., Chemam, S., Massias, L., Papy, E., Tubach, F., Wolff, M., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3276-x · Cited by 117
Duarte, R. F., López‐Jiménez, J., Cornely, O. A., Laverdière, M., HELFGOTT, D. C., Haider, S., Chandrasekar, P. H., Langston, A. A., Perfect, J. R., Ma, L., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03050-14 · Cited by 117
Zelenitsky, S. A., Rubinstein, E., Ariano, R. E., Iacovides, H., Dodek, P., Mirzanejad, Y., & Kumar, A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.015 · Cited by 116
Inflammation Is Associated with Voriconazole Trough Concentrations
van Wanrooy, M. J. P., Span, L. F. R., Rodgers, M. G. G., van den Heuvel, E. R., Uges, D. R. A., van der Werf, T. S., Kosterink, J. G. W., & Alffenaar, J. C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03820-14 · Cited by 113
Self-citationTherapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults
Lebeaux, D., Lanternier, F., Elie, C., Suarez, F., Buzyn, A., Viard, J.-P., Bougnoux, M.-E., Lecuit, M., Jullien, V., & Lortholary, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00939-09 · Cited by 105
Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers
Wattanagoon, Y., Stepniewska, K., Lindegårdh, N., Pukrittayakamee, S., Silachamroon, U., Piyaphanee, W., Singtoroj, T., Hanpithakpong, W., Davies, G., Tärning, J., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00588-08 · Cited by 102
In Vitro Studies of 5-Fluorocytosine Resistance in Candida albicans and Torulopsis glabrata
Normark, S., & Schönebeck, J. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.3.114 · Cited by 99
Falcone, M., Russo, A., Cassetta, M. I., Lappa, A., Tritapepe, L., d’Ettorre, G., Fallani, S., Novelli, A., & Venditti, M. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0559-z · Cited by 93
Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients
Miglis, C. M., Rhodes, N. J., Avedissian, S. N., Kubin, C. J., Yin, M. T., Nelson, B. C., Pai, M. P., & Scheetz, M. H. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01475-17 · Cited by 92
Maertens, J. A., Cornely, O. A., Ullmann, A. J., Heinz, W., Krishna, G., Patino, H., Caceres, M., Kartsonis, N. A., Waskin, H. A., & Robertson, M. N. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02686-13 · Cited by 90
Hoenigl, M., Duettmann, W., Raggam, R. B., Seeber, K., Troppan, K., Fruhwald, S., Prueller, F., Wagner, J., Valentin, T., Zollner-Schwetz, I., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00251-13 · Cited by 89
Fishman, J. A., Doran, M. T., Volpicelli, S. A., Cosimi, A. B., Flood, J. G., & Rubin, R. H. (2000) · Transplantation · doi:10.1097/00007890-200002150-00014 · Cited by 88
Therapeutic drug monitoring of amikacin in septic patients
Duszyńska, W., Taccone, F. S., Hurkacz, M., Kowalska−Krochmal, B., Wiela−Hojeńska, A., & Kübler, A. (2013) · Critical Care · doi:10.1186/cc12844 · Cited by 86
Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
Yi, W. M., Schoeppler, K. E., Jaeger, J., Mueller, S. W., MacLaren, R., Fish, D. N., & Kiser, T. H. (2017) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-017-0235-8 · Cited by 86
Choi, E. Y., Huh, J. W., Lim, C., Koh, Y., Kim, S., Choi, S., Kim, Y. S., Kim, M., & Hong, S. (2011) · Intensive Care Medicine · doi:10.1007/s00134-011-2130-7 · Cited by 84
Flucytosine: Correlation between Toxicity and Pharmacokinetic Parameters
Vermes, A., van der Sijs, H., & Guchelaar, H.-J. (2000) · Chemotherapy · doi:10.1159/000007260 · Cited by 84
Zelenitsky, S. A., & Ariano, R. E. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq211 · Cited by 81
Pea, F., Viale, P., Cojutti, P., & Furlanut, M. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01291-12 · Cited by 78
Self-citationRoberts, J. A., Stove, V. V., Waele, J. J. D., Sipinkoski, B., McWhinney, B. C., Ungerer, J. P. J., Akova, M., Bassetti, M., Dimopoulos, G., Kaukonen, K.-M., et al. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.023 · Cited by 76
Self-citationValacyclovir for Herpes Simplex Encephalitis
Pouplin, T., Pouplin, J. N., Van Toi, P., Lindegardh, N., Rogier van Doorn, H., Hien, T. T., Farrar, J., Török, M. E., & Chau, T. T. H. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01023-10 · Cited by 76
Forrest, A., Merali, S. J., Thamlikitkul, V., Giamarellos‐Bourboulis, E. J., Paterson, D. L., Li, J., Silveira, F. P., & Nation, R. L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01367-17 · Cited by 76
Hoenigl, M., Raggam, R. B., Salzer, H. J. F., Valentin, T., Valentin, A., Zollner‐Schwetz, I., Strohmeier, A. T., Seeber, K., Wölfler, A., Sill, H., et al. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.02.002 · Cited by 73
Tsubota, A., Hirose, Y., Izumi, N., & Kumada, H. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01780.x · Cited by 70
Suzuki, Y., Tokimatsu, I., Sato, Y., Kawasaki, K., Sato, Y., Goto, T., Hashinaga, K., Itoh, H., Hiramatsu, K., & Kadota, J. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.05.025 · Cited by 70
Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations
Ventura, M. A. E., van Wanrooy, M. J. P., Span, L. F. R., Rodgers, M. G. G., van den Heuvel, E. R., Uges, D. R. A., van der Werf, T. S., Kosterink, J. G. W., & Alffenaar, J. C. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02830-15 · Cited by 70
Self-citationHorcajada, J. P., Sorlí, L., Luque, S., Benito, N., Segura, C., Campillo, N., Montero, M., Esteve, E., Mirelis, B., Pomar, V., et al. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.08.020 · Cited by 70
Maseda, E., Grau, S., Luque, S., Castillo-Mafla, M.-P., Suárez-de-la-Rica, A., Feijoo, A. M., Salgado, P. P. C. D. A., Giménez, M.-J., García-Bernedo, C. A., Gilsanz, F., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2019-8 · Cited by 69
Self-citationPharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
Takeda, Y., Matsumoto, K., Watanabe, E. M., Kanazawa, N., Fukamizu, T., Shigemi, A., Yokoyama, Y., Ikawa, K., & Morikawa, N. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s96143 · Cited by 68
Kim, S., Yim, D., Choi, S., Kwon, J., Han, S., Lee, D., Park, C., Kwon, E.-Y., Park, S. H., Choi, J., et al. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.06.004 · Cited by 67
Aitken, S. L., Altshuler, J., Guervil, D. J., Hirsch, E. B., Ostrosky-Zeichner, L. L., Ericsson, C. D., & Tam, V. H. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.12.018 · Cited by 67
Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples
Kubin, C. J., Nelson, B. C., Miglis, C. M., Scheetz, M. H., Rhodes, N. J., Avedissian, S. N., Cremers, S., & Yin, M. T. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01493-17 · Cited by 67
Mistry, G. C., Migoya, E., Deutsch, P. J., Winchell, G., Hesney, M., Li, S., Bi, S., Dilzer, S., Lasseter, K. C., & Stone, J. A. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007303764 · Cited by 66
Shields, R. K., Clancy, C. J., Vadnerkar, A., Kwak, E. J., Silveira, F. P., Abdel-Massih, R. C., Pilewski, J. M., Crespo, M. M., Toyoda, Y., Bhama, J. K., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01325-10 · Cited by 66
Delattre, I., Musuamba, F. T., Nyberg, J., Taccone, F., Laterre, P., Verbeeck, R. K., Jacobs, F., & Wallemacq, P. E. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181f675c2 · Cited by 65
Bryant, A. M., Slain, D., Cumpston, A., & Craig, M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.021 · Cited by 64
Low Caspofungin Exposure in Patients in Intensive Care Units
van der Elst, K. C. M., Veringa, A., Zijlstra, J. G., Beishuizen, A., Klont, R., Brummelhuis-Visser, P., Uges, D. R. A., Touw, D. J., Kosterink, J. G. W., van der Werf, T. S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01582-16 · Cited by 64
Self-citationLilleri, D., Gerna, G., Zelini, P., Chiesa, A., Rognoni, V., Mastronuzzi, A., Giorgiani, G., Zecca, M., & Locatelli, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041648 · Cited by 61
Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients
Taubert, M., Zöller, M., Maier, B., Frechen, S., Scharf, C., Holdt, L. M., Frey, L., Vogeser, M., Fuhr, U., & Zander, J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00356-16 · Cited by 61
Hale, C. M., Seabury, R. W., Steele, J. M., Darko, W., & Miller, C. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190016642692 · Cited by 59
Heil, E. L., Nicolau, D. P., Farkas, A., Roberts, J. A., & Thom, K. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01008-18 · Cited by 59
Self-citationPopulation pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections
Paolo, A. D., Tascini, C., Polillo, M., Gemignani, G., Nielsen, E. I., Bocci, G., Karlsson, M. O., Menichetti, F., & Danesi, R. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.06.006 · Cited by 56
New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients
Cristallini, S., Hites, M., Kabtouri, H., Roberts, J. A., Beumier, M., COTTON, F. J., Lipman, J., Jacobs, F., Vincent, J., Créteur, J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00330-16 · Cited by 56
Self-citationChen, L., Wang, Y., Zhang, T., Li, Y., Meng, T., Liu, L., Hao, R., & Dong, Y. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3055-3 · Cited by 56
Eiden, C., Meniane, J.-C., Peyrière, H., Eymard‐Duvernay, S., Falher, G. L., Céballos, P., Fegueux, N., Cociglio, M., Reynes, J., & Hillaire‐Buys, D. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1288-9 · Cited by 55
Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid
Rayner, C. R., Chanu, P., Gieschke, R., Boak, L. M., & Jonsson, E. N. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008320317 · Cited by 52
Pai, M. P., Russo, A., Novelli, A., Venditti, M., & Falcone, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02355-14 · Cited by 50
Galar, A., Muñóz, P., Valerio, M., Cercenado, E., García‐González, X., Burillo, A., Sánchez-Somolinos, M., Juárez, M., Verde, E., & Bouza, E. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.015 · Cited by 49
Kovanda, L. L., Kolamunnage‐Dona, R., Neely, M. N., Maertens, J. A., Lee, M., & Hope, W. W. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix198 · Cited by 48
Self-citationSeizures associated with levofloxacin: case presentation and literature review
Bellon, A., Perez-Garcia, G., Coverdale, J., et al. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0717-5 · Cited by 47
Ghosh, N., Chavada, R., Maley, M. W., & van Hal, S. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12695 · Cited by 47
Hashemizadeh, Z., Badiee, P., Malek‐Hosseini, S. A., Shahraki, H. R., Geramizadeh, B., & Montaseri, H. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01211-17 · Cited by 46
Martial, L. C., Brüggemann, R. J. M., Schouten, J. A., van Leeuwen, H. J., van Zanten, A. R. H., de Lange, D. W., Muilwijk, E. W., Verweij, P. E., Burger, D. M., Aarnoutse, R. E., et al. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0347-2 · Cited by 45
Ramos, J. R., Ramírez, P., Gordón, M., Villarreal, E., Concha, P., Aroca, M. J. C., Frasquet, J., Miñana, M. R. M., & Castellanos-Ortega, Á. (2017) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2017.09.019 · Cited by 45
Population pharmacokinetics of daptomycin in critically ill patients
Soraluce, A., Asín‐Prieto, E., Rodríguez‐Gascón, A., Barrasa, H., Maynar, J., Carcelero, E., Soy, D., & Isla, A. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.03.008 · Cited by 42
Antimicrobial Utilisation in 37 Australian and New Zealand Intensive Care Units
Dulhunty, J. M., Paterson, D. L., Webb, S. A. R., & Lipman, J. (2011) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1103900212 · Cited by 39
Cornely, O. A., Duarte, R. F., Haider, S., Chandrasekar, P. H., HELFGOTT, D. C., Jiménez, J. L., Candoni, A., RAAD, I. I., Laverdière, M., Langston, A. A., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw079 · Cited by 39
Vezina, H. E., Brundage, R. C., & Balfour, H. H. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12343 · Cited by 38
Huurneman, L. J., Neely, M. N., Veringa, A., Docobo-Pérez, F., Ramos-Martin, V., Tissing, W. J. E., Alffenaar, J. C., & Hope, W. W. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03023-15 · Cited by 37
Self-citationAssociation between oral fluoroquinolones and seizures: A self-controlled case series study
Chui, C. S. L., Chan, E. W., Wong, A. Y. S., Root, A., Douglas, I. J., & Wong, I. C. K. (2016) · Neurology · doi:10.1212/wnl.0000000000002633 · Cited by 36
Oh, D. Y., Lowther, S., McCaw, J. M., Sullivan, S. G., Leang, S.-K., Haining, J., Arkinstall, R., Kelso, A., McVernon, J., Barr, I., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku146 · Cited by 35
Cattaneo, C. M., Panzali, A., Passi, A., Borlenghi, E., Lamorgese, C., Petullà, M., Re, A., Caimi, L., & Rossi, G. (2015) · Mycoses · doi:10.1111/myc.12326 · Cited by 35
Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease
van der Elst, K. C. M., Brouwers, C. H. S., van den Heuvel, E. R., van Wanrooy, M. J. P., Uges, D. R. A., van der Werf, T. S., Kosterink, J. G. W., Span, L. F. R., & Alffenaar, J. C. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000235 · Cited by 34
Self-citationByrne, C. J., Roberts, J. A., McWhinney, B. C., Fennell, J., O’Byrne, P., Deasy, E., Egan, S., Desmond, R. G., Enright, H., Ryder, S. A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02466-16 · Cited by 33
Self-citationProspective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population
Turner, R. B., Kojiro, K., Won, R., Chang, E., Chan, D., & Elbarbry, F. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.06.022 · Cited by 33
Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction
Undre, N. A., Pretorius, B., & Stevenson, P. (2014) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-014-0204-y · Cited by 31
Brink, A. J., Richards, G. A., Lautenbach, E., Rapeport, N., Schillack, V., van Niekerk, L., Lipman, J., & Roberts, J. A. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.01.015 · Cited by 31
Self-citationCross, L. J. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.1.95 · Cited by 31
Rayner, C. R., Bulik, C. C., Kamal, M. A., Reynolds, D. K., Toovey, S., Hammel, J., Smith, P. F., Bhavnani, S. M., Wart, S. A. V., Ambrose, P. G., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02440-12 · Cited by 30
Winter, S. D., Wauters, J., Meersseman, W., Verhaegen, J., Wijngaerden, E. V., Peetermans, W. E., Annaert, P., Verelst, S., & Spriet, I. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.11.009 · Cited by 30
Gómez‐López, A., Cendejas‐Bueno, E., Cuesta, I., García‐Rodríguez, J., Rodríguez-Tudela, J. L., Gutiérrez-Altés, A., & Cuenca‐Estrella, M. (2012) · Medical Mycology · doi:10.3109/13693786.2011.630039 · Cited by 29
Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy
Blaser, J., Joos, B., Opravil, M., & Luthy, R. P. (1993) · Infection · doi:10.1007/bf01728888 · Cited by 26
Tremor: a newly described adverse event with long-term itraconazole therapy
Lestner, J. M., & Denning, D. W. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.174706 · Cited by 23
Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
Sime, F. B., Stuart, J., Butler, J., Starr, T., Wallis, S. C., Pandey, S., Lipman, J., & Roberts, J. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00242-18 · Cited by 23
Self-citationMartirosov, D. M., Bidell, M. R., Pai, M. P., Scheetz, M. H., Rosenkranz, S., & Lodise, T. P. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.03.008 · Cited by 20
Reddy, M. B., Yang, K.-H., Rao, G. G., Rayner, C. R., Nie, J., Pamulapati, C. R., Marathe, B. M., Forrest, A., & Govorkova, E. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138069 · Cited by 14
Drusano, G. L., Aweeka, F. T., Gambertoglio, J. G., et al. (1996) · PubMed · Cited by 13
Itraconazole concentrations during continuous haemodiafiltration
Coronel, B., Persat, F., Dorez, D., Moskovtchenko, J.-F., PEINS, M. A., & Mercatello, A. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.3.448 · Cited by 12
Carlier, M., Athanasopoulos, A., Borrey, D., Colin, P. J., COTTON, F. J., Denooz, R., Neels, H. M., Spriet, I., Ghys, T., Verstraete, A., et al. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000467 · Cited by 6
Cited by
From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
Wicha, S. G., Märtson, A., Nielsen, E. I., Koch, B. C. P., Friberg, L. E., Alffenaar, J., Minichmayr, I. K., & the International Society of Anti‐Infective Pharmacology (ISAP), T. P. S. G. O. T. E. S. O. C. M. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2202 · Cited by 322
Self-citationSurviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Self-citationAntifungal Drugs TDM: Trends and Update
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000952 · Cited by 81
Hurkacz, M., Dobrek, L., & Wiela-Hojeńska, A. (2021) · Molecules · doi:10.3390/molecules26247456 · Cited by 60
Optimal antibiotic use in the intensive care unit
Micek, S. T., Vazquez Guillamet, M. C., Reynolds, D., Matuszak, S., Kolodziej, L., & Kollef, M. H. (2025) · Critical Care · doi:10.1186/s13054-025-05653-8 · Cited by 11
Metadata
- Authors
- Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., Timsit, J. F., Udy, A. A., Wicha, S. G., Zeitlinger, M., De Waele, J. J., Roberts, J. A., the Infection Section of European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), & Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC)
- Venue
- Intensive Care Medicine
- Published
- 2020-05-07
- Volume
- 46
- Issue
- 6
- Pages
- 1127-1153
- ISSN
- 0342-4642 (ISSN-L)
- 1432-1238
- OpenAlex
- W3022327571
- Cited by
- 1,081
- References
- 175
- FWCI
- 64.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.